Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 04:30:31 2024-07-01 EDT			5-day change	1st Jan Change
2.45 ^EUR	+4.48%		-0.41%	-63.43%

06-25	France's Carmat Names New Chairman	MT
06-25	Carmat: changes in corporate governance	CF

Carmat Provides Sales Guidance for the Second Quarter of 2021

February 10, 2021 at 01:00 am

Carmat provided sales guidance for the second quarter of 2021. The company announced that the first sales are expected in the second quarter of 2021, following the CE marking received on December 22, 2020.

Latest news about CARMAT

France's Carmat Names New Chairman	06-25	MT
Carmat: changes in corporate governance	06-25	CF
Carmat appoints its main shareholder as Chairman of the Board of Directors	06-25	RE
France's Carmat appoints biggest shareholder as board chairman	06-25	RE
Carmat SA Announces Board Changes	06-25	CI
Carmat: surrounded by analysts' comments	06-19	CF
Euroland Corporate Starts Carmat at Buy	06-19	MT
CARMAT : EuroLand Corporate initiates buy coverage	06-19	CF
Carmat: under pressure after equitization operation	06-14	CF
CARMAT : Invest Securities remains Buy, lowers its target	05-21	CF
Oddo BHF Cuts Carmat PT, Affirms Neutral Rating	05-17	MT
CARMAT : price target lowered by Oddo BHF	05-17	CF
Carmat Raises EUR16 Million for Ongoing Operations, Clinical Trial	05-17	MT
Carmat: 16 million euros successfully raised	05-17	CF
Carmat: launches a fund-raising campaign of around €15 million	05-16	CF
Carmat "optimistic" about its artificial heart clinical trial, share price rises	05-06	RE
Carmat: progress in ongoing clinical study	05-06	CF
CARMAT Continues to Build on Its Momentum in the EFICAS Study	05-06	CI
Carmat SA Reiterates Sales Guidance for the Year 2024	05-06	CI
Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
MARKET UPDATE-Consolidation in equities ahead of inflation figures	03-25	RE
Europe stable as we await further inflation data	03-25	RE
Carmat: final agreement with creditors	03-25	CF
Carmat Secures Two-year Extensions for Bank Loans	03-25	MT
CARMAT Announces a Final Agreement with All Its Financial Creditors on New Repayment Terms for Its Bank Loans	03-22	CI

Chart CARMAT

Duration

Period

More charts

Company Profile

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-10 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for CARMAT

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.345 EUR

Average target price

12.32 EUR

Spread / Average Target

+425.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
CARMAT	-63.43%	86.57M
STRYKER CORPORATION	+13.62%	130B
SMITH & NEPHEW PLC	-8.89%	10.81B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-18.14%	7.12B
GLAUKOS CORPORATION	+48.89%	6.46B
INSPIRE MEDICAL SYSTEMS, INC.	-34.21%	3.98B
AXONICS, INC.	+8.03%	3.43B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-18.50%	1.91B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-24.94%	1.66B
DOUBLE MEDICAL TECHNOLOGY INC.	-36.36%	1.47B

Medical Devices & Implants